InflaRx (IFRX) Company Report

InflaRx presented positive data for its small oral C5aR inhibitor (904) in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). In HS, the 120 mg dose demonstrated the best performance across various metrics, including draining tunnels and patient-reported outcomes. For CSU, the 60 mg dose showed a clear and consistent effect on the Urticaria Activity Score.
The company's drug (904) exhibits a much faster and higher exposure compared to Avacopan, achieving a 10x higher area under the curve (AUC) increase and reaching in the first week levels that Avacopan takes 13 weeks to achieve.
InflaRx has completed required toxicology studies for indefinite dosing and plans a larger phase 2b study for HS, likely incorporating the 120 mg dose. Discussions with the FDA are underway, with HS as the initial priority.
As of the end of Q3, InflaRx reported EUR 44.4 million (over $50 million) in cash, providing a financial runway into 2027.

Nov 11, 2025, 7:30 PM

InflaRx Announces Topline Phase 2a Data for INF904

IFRX

Product Launch

New Projects/Investments

InflaRx (Nasdaq: IFRX) announced topline Phase 2a data for INF904 in Hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) on November 10, 2025.
The Phase 2a trials for INF904 reported no signals of safety concern in both HS and CSU patients.
For HS, INF904 demonstrated biologic-like efficacy within the first 4 weeks, with HiSCR and AN count reductions comparable to successful Phase 3 comparators, and an average ~65% reduction in pain (NRS30) at week 4.
In CSU, INF904 effectively reduced UAS7 scores in both anti-IgE naive and experienced patients and demonstrated consistent improvement in angioedema up to week 4.
INF904 also exhibited a superior pharmacokinetic/pharmacodynamic (PK/PD) profile and faster therapeutic exposure compared to reported avacopan data.

Nov 10, 2025, 1:00 PM

InflaRx Regains Nasdaq Minimum Bid Price Compliance

IFRX

Delisting/Listing Issues

InflaRx N.V. has regained compliance with the Nasdaq Minimum Bid Price Requirement, as confirmed by Nasdaq on September 11, 2025.
This compliance was achieved because the closing bid price of the company's ordinary shares was $1.00 or greater for 10 consecutive business days, from August 27, 2025, to September 10, 2025.
InflaRx was initially notified of non-compliance on July 11, 2025, after its share price fell below $1.00 for 30 consecutive business days.

Sep 12, 2025, 8:05 PM

Earnings Transcripts

Quarterly earnings call transcripts for InflaRx.

Nov 7, 2019

Get instant answers from SEC filings, earnings calls & more